Newsroom

LEAWOOD, Kan.--(BUSINESS WIRE)--AMC Entertainment (NYSE: AMC), the largest theatrical exhibitor in the United States and the world, once again welcomed global audiences in significant numbers to its theaters across the U.S. and internationally, as MICHAEL moonwalked to the strongest biopic opening in box office history. These reported opening numbers for MICHAEL include Friday through Sunday attendance figures, along with its Wednesday and Thursday preview screenings. As a result of the media-r...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 24.04.2026 FVD. IE00BKVKW020 250,002.00 USD 7,271,227.55 29.085  ...

CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 24.04.2026 FCSG IE00BKPSPT20 1,025,002.00 USD 43,523,547.14 42.462  ...

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled medical transportation and mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31, 2026 after the markets close on Monday, May 11, 2026. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Monday, May 11, 2026 5:00 p.m....

NEW YORK--(BUSINESS WIRE)--The AIG Board of Directors announced today that effective June 1, 2026, Eric Andersen will become President and Chief Executive Officer of AIG and join the AIG Board of Directors and Peter Zaffino will become Executive Chair of the AIG Board of Directors, marking the successful conclusion of the company’s previously announced leadership transition plan. “I want to express my appreciation and gratitude to Peter Zaffino for his tremendous leadership, tireless commitment...

FORT WORTH, Texas--(BUSINESS WIRE)--Presidio Production Company (NYSE: FTW) (“Presidio” or the “Company”), a yield-focused, differentiated oil and gas operator in the United States focused on the acquisition and optimization of producing oil and natural gas wells, without drilling, today announced that it will report first quarter 2026 results on Friday, May 15th, 2026. The Company will host an earnings conference call that morning at 11:00 AM ET / 10:00 AM CT to discuss financial results and b...

NEW YORK--(BUSINESS WIRE)--Impactive Capital, LP (“Impactive” or “we”), together with its affiliates, is one of the largest shareholders of WEX Inc. (NYSE: WEX) (the “Company” or “WEX”) with an ownership interest of approximately 4.9%. Impactive announced today that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended that shareholders vote on the WHITE proxy card FOR the election of Impactive director nominees Kurt Adams and Lauren Taylor Wolfe to the Com...

NEW YORK--(BUSINESS WIRE)--Today, SharonAI Holdings Inc. (NASDAQ:SHAZ) and its subsidiaries (“Sharon AI” or “the Company”), a leading Australian Neocloud, announced that it has entered into definitive agreements for the purchase of US$350 million of 6% Convertible Senior Notes due in 2031 (the “Notes”). The issue price for the Notes will equal 100% of the principal amount thereof. The Notes will be sold in a private offering pursuant to Rule 4(a)(2) of the Securities Act of 1933, as amended (th...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS® System Post-Approval Study (PAS) in Neurology, alongside the Company’s recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meet...